ADC Therapeutics director reports RSU grant, tax withholding

ADC Therapeutics SA director Timothy Coughlin reported routine equity compensation activity.

Rhea-AI Filing Summary

ADC Therapeutics SA director Timothy Coughlin reported routine equity compensation activity. On June 1, 2026, he received an annual grant of 45,000 common shares in the form of restricted stock units under the company’s 2019 Equity Incentive Plan for service as a director.

On June 3, 2026, 12,600 common shares were withheld by the company to cover his tax obligations when previously granted restricted share units vested. This tax withholding is shown as a disposition but is not an open‑market sale. After these transactions, he directly holds 72,400 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Coughlin Timothy

Role Director

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	12,600	$3.08	$39K
Grant/Award	Common Shares	45,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 72,400 shares (Direct)

Footnotes (2)

1. F1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Key Figures

RSU grant: 45,000 shares Tax withholding shares: 12,600 shares Post-transaction holdings: 72,400 shares +1 more

4 metrics

RSU grant 45,000 shares Annual director RSU grant on June 1, 2026

Tax withholding shares 12,600 shares Shares withheld for tax on June 3, 2026

Post-transaction holdings 72,400 shares Common shares held directly after transactions

Withholding price $3.08 per share Value used for 12,600-share tax withholding

Key Terms

restricted stock units, 2019 Equity Incentive Plan, tax withholding obligations, contingent right

4 terms

restricted stock units financial

"Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2019 Equity Incentive Plan financial

"made under the Issuer's 2019 Equity Incentive Plan for service as a Director"

tax withholding obligations financial

"Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADC Therapeutics (ADCT) director Timothy Coughlin report?

Timothy Coughlin reported an equity grant and a related tax withholding. He received 45,000 restricted stock units, then 12,600 common shares were withheld to satisfy tax obligations on vested awards, reflecting routine director compensation rather than open-market trading activity.

How many ADC Therapeutics (ADCT) shares does Timothy Coughlin hold after this Form 4?

Following these transactions, Timothy Coughlin directly holds 72,400 common shares of ADC Therapeutics. This figure reflects the 45,000-share restricted stock unit grant and the subsequent withholding of 12,600 shares to cover tax obligations tied to vesting of earlier awards.

Was there an open-market sale of ADC Therapeutics (ADCT) shares in this Form 4?

No open-market sale occurred in this Form 4. The only disposition, coded “F,” represents 12,600 shares withheld by ADC Therapeutics to satisfy Timothy Coughlin’s tax obligations from vesting restricted share units, rather than a discretionary sale into the market.

What is the nature of the 45,000-share award to ADC Therapeutics (ADCT) director Coughlin?

The 45,000-share award is an annual grant of restricted stock units for service as a director under ADC Therapeutics’ 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one common share, subject to vesting conditions tied to service.

When do Timothy Coughlin’s new ADC Therapeutics (ADCT) RSUs vest?

The new restricted stock units vest on the earlier of one year from the grant date or the date of ADC Therapeutics’ 2027 Annual Meeting of Shareholders. Vesting is conditioned on Timothy Coughlin’s continued service to the company as described in the footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/01/2026		A		45,000(1)	A	$0	85,000	D
Common Shares	06/03/2026		F(2)		12,600	D	$3.08	72,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-fact for Timothy Coughlin	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)